Overview: What is Hereditary Angioedema?

Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic condition characterized by recurrent episodes of severe swelling (angioedema) in various body parts. Attacks may affect the limbs, face, intestinal tract, and—most dangerously—the airway. HAE differs from allergic forms of angioedema in its lack of urticaria (hives), its underlying mechanisms, and its genetic inheritance patterns.

Global Prevalence and Demographics

• HAE affects approximately 1 in 50,000 individuals worldwide, regardless of gender or ethnicity.
• Many cases remain undiagnosed or misdiagnosed due to unfamiliarity among clinicians.
• Symptoms generally emerge in late childhood or adolescence, but delayed diagnosis is common.

Genetic Causes and Types of HAE

• HAE Type I (≈85% of cases): Low levels of functional C1 inhibitor (C1-INH) protein.
• HAE Type II (≈15%): Normal or elevated quantities, but dysfunctional C1-INH.
• HAE with normal C1-INH (formerly Type III): Rare and typically involves other genes such as F12 (encoding coagulation factor XII), PLG, ANGPT1, and others. Most often affects women and may be triggered by estrogen exposure.
• Inheritance is broadly autosomal dominant, but up to a quarter arise from new (de novo) mutations.

Mutations leading to HAE result in impaired regulation of the complement and contact (kallikrein-kinin) systems, causing excessive bradykinin production and subsequent swellings.

Pathophysiology: Why Does Swelling Occur?

The hallmark of HAE is a temporary increase in vascular permeability due to unrestrained bradykinin activity. Bradykinin acts on the endothelium, causing leakage of plasma and swelling. Importantly, histamine release (as seen in allergies) is not the main cause—antihistamines and corticosteroids are ineffective for HAE attacks.

Symptoms and Attack Features

• Localized swelling in the extremities, face, genitals, or trunk (often asymmetric)
• Abdominal attacks: severe pain, vomiting, diarrhea, and possible misdiagnosis as surgical emergencies
• Laryngeal (throat) edema: hoarseness, difficulty breathing—requires emergency intervention
• Attacks develop gradually (hours), last 2–5 days, and resolve spontaneously
• No itching or hives (urticaria)

Prodromal signs may include tingling, fatigue, or a non-raised red rash (erythema marginatum).

Triggers of HAE Attacks

• Physical trauma (dental work, surgery, medical procedures)
• Stress (emotional or physical)
• Hormonal changes (menstruation, pregnancy, estrogen-containing medications)
• Infections, illness
• Certain medications (ACE inhibitors especially)
• Often, no clear trigger can be identified

Hereditary Angioedema with Normal C1 Inhibitor: Modern Diagnosis, Genetics & Treatment Advances

Hereditary Angioedema (HAE) with Normal C1 Inhibitor (C1-INH) represents a challenging and evolving field in allergy and immunology. This rare angioedema subtype differs from the more common HAE Types I and II, with distinctive diagnostic, genetic, and therapeutic considerations. Recent clinical research has further clarified various aspects, but significant questions remain. Below is a comprehensive overview for clinicians and patients.

Diagnostic Approach

• Confirm true angioedema: Not all swelling is angioedema; clinical evaluation and photographic documentation may assist.
• Rule of “angioedema without urticaria” is no longer absolute—exceptions are well recognized.
• Thorough family and medication history are essential; heredity and medication triggers must be considered.
• Order laboratory tests for C4 and functional C1-INH levels to rule out HAE Types I and II; C1q may be tested as indicated.
• Exclude mast cell–mediated angioedema using high-dose antihistamines, montelukast (if no contraindications), and omalizumab trials.
• If hereditary pattern present, consider genetic panel for known HAE-associated mutations (e.g., F12, PLG, ANGPT1).
• Utilise whole-exome sequencing for difficult cases where standard panels do not identify a causative mutation.
• Screening all at-risk family members is strongly encouraged, since initial presentation may be severe/fatal.

Genetics and Emerging Phenotypes

• At least six gene mutations now associated with HAE with normal C1-INH: F12 (Factor XII), PLG (Plasminogen), ANGPT1 (Angiopoietin-1), as well as rare mutations in kininogen, MYOF (myoferlin), and pathways impacting heparan sulfate or carboxypeptidase N.
• Inheritance is typically autosomal dominant with variable penetrance; family and national founder effects influence prevalence.
• Phenotypes may include unique features such as tongue angioedema (notably in PLG gene cases), estrogen-dependence (factor XII), and varying response to therapies based on mutation.

Pathophysiology Insights

• Contact system activation/kinin generation—mutations may bypass traditional pathways (notably in PLG-related angioedema).
• Disruption of vascular permeability also involves bradykinin, VEGF, and endothelial signaling (e.g., reduced angiopoietin/Tie2 pathway activity).
• Disease mechanisms remain poorly understood in most idiopathic and non-hereditary cases.

Current Treatment Landscape

• Evidence for therapy is emerging, but few high-quality trials exist. Many treatments are based on case series/expert opinion (2024 guidelines).
• Avoid triggers and treat acute attacks promptly.
• Icatibant and C1-INH concentrates show efficacy as on-demand therapy in diverse genetic and idiopathic HAE with normal C1-INH cases.
• Tranexamic acid is especially effective in PLG mutation cases and can be considered in estrogen-dependent/factor XII-related cases.
• Progesterone may have a role in female, hormone-sensitive Factor XII HAE.
• Lanadelumab is less effective in PLG-HAE (contact system–independent), but select cases may respond.
• Refractory cases: Reassess diagnosis and trial additional gene-directed or exome-based evaluation.

Unmet Needs and Future Directions

• Biomarker research is a critical priority to speed and clarify diagnosis with less invasive workup.
• Better tailored therapies will require more robust clinical studies and mechanistic understanding across genetic subtypes.

References

• Busse P, Christiansen S, et al. Diagnosis and Management of HAE with Normal C1 Inhibitor: An Update. J Allergy Clin Immunol Pract. 2023;11(2):481–493.
• Zuraw BL, Aygören-Pürsün E, et al. HAE with Normal C1-INH: Novel Mutations and Therapies. Curr Opin Allergy Clin Immunol. 2024;24(1):12–18.
• International WAO/EAACI Consensus Document on the Management of HAE. Allergy. 2024;79(5):1097–1115.

This summary does not replace individualized medical advice. Patients should consult a clinical immunologist or HAE specialist for diagnosis and treatment recommendations.

Modern Classification: DANCE System

The DANCE (Definition, Acronyms, Nomenclature, and Classification of Angioedema) system, published internationally in 2024, brings a mechanism-driven approach to angioedema disorders, including HAE. DANCE divides angioedema into five types (endotypes):

• Mast cell-mediated angioedema (e.g., allergic or idiopathic forms)
• Bradykinin-mediated angioedema (includes HAE with C1-INH deficiency or dysfunction)
• Vascular endothelial dysfunction
• Drug-induced angioedema (e.g., ACE inhibitors, DPP-4 inhibitors)
• Angioedema of unknown mechanism (formerly “idiopathic”)

This modern classification clarifies distinctions and fosters a unified clinical and research language, ensuring HAE gets recognized for its unique pathophysiology among the angioedemas.

Diagnosis

• Clinical suspicion based on symptoms and family history
• Complement testing: low C4, low C1-INH protein level and/or function in classic HAE
• Genetic testing for SERPING1 and rare gene variants in cases of normal C1-INH
• Rule out acquired angioedema and allergic causes

Misdiagnosis as allergy or other GI/surgical disorders is common—expert evaluation by an allergist/immunologist is vital.

Management of HAE

Acute Treatment

• C1-INH concentrate (IV, SC): first-line therapy for all attack types
• Bradykinin B2 receptor antagonist (icatibant): effective for rapid symptom relief
• Kallikrein inhibitor (ecallantide): for acute attacks (some countries)
• Fresh frozen plasma: may be used when other agents are not available
• Note: Antihistamines, steroids, and epinephrine are not effective

Long-Term Prophylaxis

• C1-INH prophylactic infusions (IV or SC)
• Kallikrein inhibitors (lanadelumab, berotralstat)
• Androgens (danazol, stanozolol)—less favored due to side effects
• Antifibrinolytics (tranexamic acid)—less effective, considered in certain cases
• Management of triggers and patient education

Self-Administration

Home therapy and self-injection has revolutionised care. All patients at risk for laryngeal involvement should have on-demand medication accessible at all times.

Prognosis and Quality of Life

• Untreated, HAE can cause considerable morbidity and risk of fatal airway attacks
• With modern therapies, most patients lead normal lives, though attack unpredictability causes anxiety
• Access to modern management remains uneven globally; patient advocacy is important

Living with HAE & Support Resources

• Ensure emergency action plans are in place
• Educate family, friends, and employers about the condition
• Seek genetic counseling for family planning
• Connect with HAE patient organizations (e.g., HAEA, HAEi) for community and information

Frequently Asked Questions (FAQ)

• Q: Can HAE be cured?
  A: No, but it is manageable with the right therapy.
• Q: How is HAE different from allergies?
  A: HAE is not driven by histamine or IgE and does not cause hives. It is bradykinin-mediated.
• Q: Should I avoid dental or surgical procedures?
  A: You should plan such procedures only with your care team, who can arrange for pre-procedure prophylaxis.
• Q: What should I do in an emergency?A: Seek immediate medical attention. Carry medical alert information and your on-demand therapy at all times.

References

1. Busse PJ et al. Hereditary Angioedema: Diagnosis, Management, and Advances in Therapy. J Allergy Clin Immunol Pract. 2021.
2. Avner et al. DANCE: Definition, Acronyms, Nomenclature, and Classification of Angioedema. J Allergy Clin Immunol. 2024.
3. U.S. Hereditary Angioedema Association (HAEA). www.haea.org
4. HAE International (HAEi). www.haei.org